HeartSciences Inc. (HSCS) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of HeartSciences Inc. stock $1.79, price $2.13, that is 15.8% below the price, quality 17 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
HeartSciences Inc.
HSCS · USExpensive (fair value 16% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
53‑month range $0.0170 – $340.00 · fair‑value band $1.34 – $2.23 · the $2.13 price screens above the $1.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether HeartSciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence.
Show moreShow less
It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform.
The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Stock analysis
HeartSciences Inc. (HSCS) currently trades at $2.13, while our estimate is $1.79, 16% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.34 (bear) to $2.23 (bull), the price of $2.13 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
HeartSciences Inc. reported revenue of $4.3K in FY2026 versus $14.4K in FY2022, a compound −26.0%/yr. Reported net income was −$9.1M in FY2026.
Key figures
Market cap $10.3M Micro · EPS (TTM) $−3.21 · Return on equity −1,852% · Return on assets (EBIT) −135% (5-year average) · Operating margin −139,957% · Revenue (TTM) $4.5K · Revenue growth (YoY) +10.5% · Free cash flow −$7.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −16%, HSCS screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗
Revenue & earnings trend
HSCS screens overvalued: fair value 16% below the price. Compare with Abbott Laboratories, →
Compare HeartSciences Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks
Valuation Multiplesvs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Stryker Corporation SYK | $309.64 | $340.60 | +10% | vs HSCS |
| Boston Scientific Corporation BSX | $44.34 | $48.77 | +10% | vs HSCS |
| DexCom, Inc DXCM | $83.33 | $91.66 | +10% | vs HSCS |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥184.30 | ¥197.34 | +7% | vs HSCS |
| STERIS plc STE | $264.32 | $281.90 | +7% | vs HSCS |
| GE HealthCare Technologies Inc GEHC | $83.02 | $69.92 | −16% | vs HSCS |
| Edwards Lifesciences Corporation EW | $107.15 | $81.94 | −24% | vs HSCS |
| Medtronic plc MDT | $102.86 | $74.90 | −27% | vs HSCS |
| Abbott Laboratories, ABT | $108.52 | $75.28 | −31% | vs HSCS |
| Koninklijke Philips N.V PHIA | €27.54 | €15.23 | −45% | vs HSCS |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is HeartSciences Inc. (HSCS) overvalued or undervalued?
What is the fair value of HSCS?
What is the quality score of HSCS?
What is the price target for HeartSciences Inc. (HSCS)?
What is the HeartSciences Inc. stock forecast for 2026?
What is the revenue of HeartSciences Inc. (HSCS)?
What is the intrinsic value of HeartSciences Inc. (HSCS)?
Is HeartSciences Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of HSCS?
How much is HeartSciences Inc. worth?
What do the bullish and bearish scenarios say about HSCS?
How solid is the balance sheet of HeartSciences Inc. (HSCS)?
How far is HSCS from its 52-week high?
Which stocks are comparable to HeartSciences Inc.?
Is HeartSciences Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of HeartSciences Inc. (HSCS)?
What should I pay attention to with HeartSciences Inc. right now?
Key figures of HeartSciences Inc.
How large is the market capitalisation of HeartSciences Inc. (HSCS)?
What are the earnings per share of HeartSciences Inc. (HSCS)?
What is the return on equity of HeartSciences Inc. (HSCS)?
What is the EBIT return on assets of HeartSciences Inc. (HSCS)?
What is the operating margin of HeartSciences Inc. (HSCS)?
How fast is revenue growing at HeartSciences Inc. (HSCS)?
How much free cash flow does HeartSciences Inc. (HSCS) generate?
How much net debt does HeartSciences Inc. (HSCS) carry?
Watch HeartSciences Inc. in the live analysis
One click puts HeartSciences Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.